Combining structure-based drug design and pharmacophores.

Development towards integrated computer-aided drug design methodologies is presented by utilising crystal structure complexes to produce structure-based pharmacophores. These novel pharmacophores represent the ligand features that are involved in interactions with the target protein, as well as the space around the ligand occupied by the protein. The protein-ligand complexes can also yield information about all interactions that ligands could potentially form with the binding site, as well as about the size of the binding cavity. Together, these describe a 'superligand', which can also be viewed as a pharmacophore. Various types of novel pharmacophores are discussed and compared, using HIV-1 reverse transcriptase (RT) as the target protein, and their application in database searching is presented.

[1]  P A Keller,et al.  Development of computational and graphical tools for analysis of movement and flexibility in large molecules. , 2000, Journal of molecular graphics & modelling.

[2]  Osman F. Güner,et al.  Pharmacophore perception, development, and use in drug design , 2000 .

[3]  F. Bushman,et al.  Developing a dynamic pharmacophore model for HIV-1 integrase. , 2000, Journal of medicinal chemistry.

[4]  R. Griffith,et al.  Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase. , 1999, Bioorganic & medicinal chemistry.

[5]  Gerhard Klebe,et al.  Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. , 2003, Journal of molecular biology.

[6]  A. D. Clark,et al.  Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. , 1998, Journal of molecular biology.

[7]  Peter Zbinden,et al.  Quasi-Atomistic Receptor Surface Models: A Bridge between 3-D QSAR and Receptor Modeling , 1998 .

[8]  Renate Griffith,et al.  Novel pharmacophore-based methods reveal gossypol as a reverse transcriptase inhibitor. , 2003, Journal of molecular graphics & modelling.

[9]  Gerd Folkers,et al.  PrGen: Pseudoreceptor Modeling Using Receptor‐mediated Ligand Alignment and Pharmacophore Equilibration , 1998 .

[10]  Rakesh Vig,et al.  Structure-Based Design of Novel Dihydroalkoxybenzyloxopyrimidine Derivatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficiency Virus Reverse Transcriptase , 1998, Antimicrobial Agents and Chemotherapy.

[11]  Henri Moereels,et al.  Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors , 1995, Nature Structural Biology.

[12]  Gerhard Klebe,et al.  Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II. , 2001, Angewandte Chemie.

[13]  Gerhard Klebe,et al.  Utilising structural knowledge in drug design strategies: applications using Relibase. , 2003, Journal of molecular biology.

[14]  D I Stuart,et al.  Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding* , 2000, The Journal of Biological Chemistry.

[15]  L. Bladh,et al.  Pharmacophores incorporating numerous excluded volumes defined by X-ray crystallographic structure in three-dimensional database searching: application to the thyroid hormone receptor. , 1998, Journal of medicinal chemistry.

[16]  Omoshile Clement,et al.  Use of Pharmacophores in Structure-Based Drug Design , 2003 .

[17]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..